15 Cheapest Stocks Insiders Are Buying In March

13. MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA)

Market Capitalization: $48.3 million

MAIA Biotechnology is an immuno-oncology company specializing in targeted therapies aimed at enhancing the treatment of cancer. Its primary candidate, THIO, is a novel drug in clinical trials designed to target telomeres in cancer cells, specifically for non-small cell lung cancer (NSCLC) patients with telomerase-positive tumors.

Recently, the company announced that preclinical data for its lead cancer treatment, the THIO dimer, was published in a scientific journal. The study showed that THIO and its dimer form effectively block a key enzyme (GSTP1) involved in cancer progression and drug resistance, suggesting the dimer could improve chemotherapy effectiveness by reducing resistance.

This month, two insiders acquired approximately $1.19 million worth of MAIA shares at an average price of $1.50 per share. Year-to-date, the stock is down 15.66%, trading at $1.67 per share. Over the past 12 months, MAIA shares lost 34.51%.

According to TipRanks, one Wall Street analyst rates MAIA stock as a “Moderate Buy” with a price target of $14.00. The price target suggests a potential upside of 738.32% from the latest price.